Case Study
CSL signs enterprise agreement with BrightInsight following success of Hizentra app
CSL Behring leveraged the BrightInsight Platform® to launch a mobile app for adult patients with rare diseases who are taking Hizentra.
Read NowCSL Behring leveraged the BrightInsight Platform® to launch a mobile app for adult patients with rare diseases who are taking Hizentra.
Read Now64
countries are deployment ready
~$35B
of combined forecast for peak annual sales for drugs and IVD assets on our platform
80%+
disease states covered
Contact us to set up a demo today.